a

Bioventus to increase Exogen clinical research — 4 key notes

Written by  Adam Schrag | Thursday, 16 March 2017 19:53
Social sharing

Durham, N.C.-based Bioventus announced it will conduct studies to further validate Exogen's ability to reduce fracture risks.

Here are four notes:

 

1. Exogen has treated over 1 million patients since being FDA PMA approved in 1994.

 

2. The system uses low-intensity pulsed ultrasound to stimulate the body's natural healing process.

 

3. The new clinical research, Bioventus Observational Non-interventional Exogen Studies, will build on previous data to develop additional clinical knowledge of the product.

 

4. Bioventus Senior Vice President and Chief Science Offer Alessandro Pavesio said, "BONES represents a significant investment in developing epidemiologically grounded rigorous clinical evidence to support use of Exogen in fractures at risk."

 

More device articles:
Baxter's FLOSEAL may yield cost savings for hospital spinal, cardiac surgeries: 4 things to know

Mizuho OSI opens 4th global training center — 5 details

Medacta reaffirms partnership with OREF — 5 observations

© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months